Neximmune Inc Stock price
Is Neximmune Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
Neximmune Inc Stock Analysis
Analyst Opinions
7 Analysts have issued a Neximmune Inc forecast:
Analyst Opinions
7 Analysts have issued a Neximmune Inc forecast:
Don't miss a Thing! We will send you all news about Neximmune Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Neximmune Inc Stock News
Company Profile
NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM. The company was founded by Kenneth C. Carter, Jonathan Schneck, and Mathias Oelke in June 7, 2011 and is headquartered in Gaithersburg, MD.
| Head office | United States |
| CEO | Mr. Jalbert |
| Employees | 6 |
| Founded | 2011 |
| Website | www.neximmune.com |


